DAC N-055

DRUG2 trials

Sponsors

Waisenmedizin e. V. Promoting Access to Essential Medicine

Conditions

Wound Healing

Phase 2

Rationale for New Topical Anthroponotic Cutaneous Leishmaniasis (ACL) Treatment in Kabul

CompletedNCT00947362

Waisenmedizin e. V. Promoting Access to Essential MedicineWound Healing

Start: 2004-08-01End: 2007-12-15Updated: 2025-08-08

Rationales for Wound Care Management in Old World Cutaneous Leishmaniasis Patients

CompletedNCT00996463

Waisenmedizin e. V. Promoting Access to Essential MedicineWound Healing

Start: 2010-01-31End: 2011-03-31Target: 63Updated: 2011-03-28

Related Papers

A randomized controlled phase IIb wound healing trial of cutaneous leishmaniasis ulcers with 0.045% pharmaceutical chlorite (DAC N-055) with and without bipolar high frequency electro-cauterization versus intralesional antimony in Afghanistan

BMC Infectious Diseases2014-11-2421 citations

Rapid Healing of Cutaneous Leishmaniasis by High-Frequency Electrocauterization and Hydrogel Wound Care with or without DAC N-055: A Randomized Controlled Phase IIa Trial in Kabul

PLoS neglected tropical diseases2014-02-1332 citations